A series of non-peptide inhibitors targeting the polo-box domain (PBD) of polo-like kinase 1 (Plk1) was designed based on the potent and selective minimal tripeptide Plk1 PBD inhibitor. Seven compounds were designed, synthesized and evaluated for fluorescence polarization (FP) assay. The most promising compound 10 bound to Plk1 PBD with IC₅₀ of 3.37 μM and had no binding to Plk2 PBD or Plk3 PBD at 100 μM. Molecular docking study was performed and possible binding mode was proposed. MM/GBSA binding free energy calculation were in agreement with the observed experimental results. These novel non-peptide selective Plk1 PBD inhibitors provided new lead compounds for further optimization.

基于有效和选择性最小的三肽Plk1 PBD抑制剂，设计了一系列针对polo样激酶1（Plk1）的polo-box域（PBD）的非肽抑制剂。设计，合成并评估了7种化合物，用于荧光偏振（FP）分析。最有希望的化合物10与Plk1 PBD结合，IC ₅₀为3.37μM，并且在100μM下不与Plk2 PBD或Plk3 PBD结合。进行了分子对接研究，并提出了可能的结合方式。MM / GBSA结合自由能的计算与观察到的实验结果一致。这些新颖的非肽选择性Plk1 PBD抑制剂为进一步优化提供了新的先导化合物。